RECOMBINANT DNA GLYCOPROTEIN VACCINE

猫疱疹病毒1型（FHV-1）是猫的主要病原体， 分布 针对FHV-1的市售活疫苗是 广泛使用，但其公认的严重缺点是缺乏完整的 病毒减毒导致疫苗诱导的发生 临床症状 拟议研究的总体目标是开发一种重组 抗FHV-1的DNA疫苗比现有疫苗更安全，免疫原性更高 产品. 在第一阶段，一组针对 FHV-1的表面糖蛋白将被开发和筛选， 抗原特异性和病毒中和能力。 这些单克隆 抗体是分离个体的基本工具 用亲和柱分析糖蛋白，绘制糖蛋白基因， 筛选表达载体产物，二期的主要目标。 该系统作为人类疱疹病毒疫苗模型的价值 发展来自于这样一个事实，即它允许定义糖蛋白 在疾病的自然宿主中诱导免疫力。

Feline herpesvirus-1 (FHV-1) is a major pathogen of cats with worldwide distribution. Commercially available live vaccines against FHV-1 are widely used but their recognized serious drawback is the lack of complete attenuation of the virus resulting in the occurrence of vaccine induced clinical signs. The overall objective of the proposed research is to develop a recombinant DNA vaccine against FHV-1 that is safer and more immunogenic then existing products. During phase I a panel of monoclonal antibodies against the surface glycoproteins of FHV-1- will be developed and screened for antigenic specificity and virus neutralizing ability. These monoclonal antibodies are the essential tools for isolation of individual glycoproteins with affinity columns, mapping of the glycoprotein genes and screening of expression vector products, the major objectives of phase II. The value of this system as a model for human herpesvirus vaccine development comes from the fact that it allows definition of glycoprotein induced immunity in the natural host of the disease.